Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Musculoskeletal and connective tissue disorders – page 49

  • 865 clinical trials
  • 357 recruiting
  • 328 conditions
  • 28 countries

Conditions in this area

328 conditions with trials, the busiest first

Rheumatoid arthritis75Osteoarthritis62Systemic lupus erythematosus61Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Sjogren's syndrome29Duchenne muscular dystrophy28Soft tissue sarcoma28Axial spondyloarthritis21Juvenile idiopathic arthritis21Back pain19Ewing's sarcoma19Lupus nephritis18Spinal muscular atrophy17Dermatomyositis15Cutaneous lupus erythematosus14Glycogen storage disease type II14Myotonic dystrophy12Osteochondrodysplasia12Osteosarcoma12Rhabdomyosarcoma11Sarcoma11Osteoporosis10+304

Clinical trials in Musculoskeletal and connective tissue disorders

865 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

865 clinical trials

Adrenoleukodystrophy+1

Not recruiting

Study on Pramipexole for Treating Restless Legs in Women with X-linked Adrenoleukodystrophy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pramipexole Dihydrochloride Monohydrate
  • Sponsor:Amsterdam UMC Stichting

Fibrodysplasia ossificans progressiva

Not recruiting

Study on the Safety and Effects of Saracatinib for Patients with Fibrodysplasia Ossificans Progressiva (FOP)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:SARACATINIB
  • Sponsor:Amsterdam UMC Stichting

Soft tissue sarcoma

Not recruiting

Study of Cirtuvivint for Patients with Advanced Soft-Tissue Sarcomas as a Second-Line Treatment

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CIRTUVIVINT
  • Sponsor:Asociacion Europea Y Latinoamericana SELNET Para La Investigacion En Sarcomas

Soft tissue sarcoma

Not recruiting

Study of PM14 Alone and with Radiotherapy for Patients with Advanced Soft Tissue Sarcomas and Other Solid Tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ecubectedin
  • Sponsor:Asoc Grupo Espanol De Investigacion En Sarcomas

Duchenne muscular dystrophy

Not recruiting

Study on Metoprolol for Preventing Heart Disease in Boys with Duchenne Muscular Dystrophy Aged 8-17

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Metoprolol Tartrate
  • Sponsor:Medical University Of Gdansk

Myasthenia gravis

Not recruiting

Study on Rituximab for Patients with Generalized Myasthenia Gravis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Polymyalgia rheumatica

Not recruiting

Study on Baricitinib for New-Onset Polymyalgia Rheumatica Patients to Reduce Steroid Use

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Medical University Of Vienna

Neuroendocrine carcinoma of the skin+4

Not recruiting

Study of BT-001 and Pembrolizumab for Patients with Advanced Solid Tumors, Including Sarcoma, Merkel Cell Carcinoma, Melanoma, Breast, and Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bt-001
  • Sponsor:Transgene

Obesity+1

Not recruiting

Study on the Effects of KBP-336 and Paracetamol for Obese Patients with Knee Osteoarthritis

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Kbp-336
  • Sponsor:KeyBioscience S.A.

Chondropathy

Not recruiting

Study on Autologous Chondrocytes and Remestemcel for Knee Cartilage Lesions in Patients with Symptomatic Articular Cartilage Damage

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Remestemcel
  • Sponsor:Universitair Medisch Centrum Utrecht

Polymyalgia rheumatica

Not recruiting

Study on Rituximab for Reducing Steroid Use in Newly Diagnosed Polymyalgia Rheumatica Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Sint Maartenskliniek

Arthralgia

Not recruiting

Study on [18F]Fluoro-PEG-Folate PET Scans for Identifying Rheumatoid Arthritis Risk in Individuals with ACPA Positive Arthralgia

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:[18F]Fluoro-Peg-Folate
  • Sponsor:Amsterdam UMC Stichting

Substances studied in this area

The therapies tested most often in Musculoskeletal and connective tissue disorders trials.

Sodium Chloride47 clinical trialsParacetamol32 clinical trialsTocilizumab29 clinical trialsMethotrexate25 clinical trialsAdalimumab24 clinical trialsRituximab23 clinical trialsCyclophosphamide20 clinical trialsEtanercept20 clinical trialsBaricitinib17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.